Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2020
Event: Entry into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:
- Shares Offered: 11,000,000 shares of Common Stock.
- Offering Price: $12.00 per share.
- Over-Allotment Option: Underwriters granted an option to purchase an additional 1,650,000 shares.
- Expected Net Proceeds: Approximately $123.8 million from the base offering; approximately $142.4 million if the over-allotment option is fully exercised.
- Underwriters: J.P. Morgan Securities LLC and Piper Sandler & Co.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the anticipated increase in cash liquidity resulting from the equity offering. The company expects to close the transaction on May 14, 2020, subject to customary closing conditions.
Outlook and Management Commentary
Management has secured financing to support the company's operations. The offering is being made pursuant to a shelf registration statement on Form S-3. The filing incorporates the Underwriting Agreement and a legal opinion regarding the issuance of shares by reference.
Investor Verification Checklist
- Confirm the closing date of the offering (expected May 14, 2020).
- Verify whether the underwriters exercise the 1,650,000 share over-allotment option.
- Review the final net proceeds after actual underwriting discounts and offering expenses.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and dilution metrics.